Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Docetaxel albumin bound’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel albumin bound overview
Docetaxel albumin bound is under development for the treatment of solid tumor like prostate cancer and gastric cancer, gastroesophageal junction adenocarcinoma, gastroesophageal (GE) junction carcinomas, recurrent or metastatic head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer and hypopharyngeal cancer, lung cancer, ovarian cancer metastatic breast cancer, metastatic prostate cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer and pancreatic cancer. It administered through intravenous drip route. It acts by targeting tubulin.
CSPC Pharmaceutical Group overview
CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, common generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and childhood acute lymphoblastic leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
For a complete picture of Docetaxel albumin bound’s drug-specific PTSR and LoA scores, buy the report here.